Skip to main content
Journal of Psoriasis and Psoriatic Arthritis logoLink to Journal of Psoriasis and Psoriatic Arthritis
. 2025 May 30;10(4):115–123. doi: 10.1177/24755303251344155

All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis

Alice B Gottlieb 1, Hannah Crooke Kwiatkowski 2, Juan Semeco 2, Bhargav Lakshminarasimhan 2, Bruce Strober 3, Mark Lebwohl 1,✉
PMCID: PMC12125009  PMID: 40454110

Abstract

Background

Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US.

Objective

To compare all-cause mortality among patients with GPP with matched populations of patients with plaque psoriasis (PsO) and the general population in the US.

Methods

An observational study was conducted using US claims data collected between January 1, 2016 and December 31, 2019. All-cause mortality was evaluated at 365 days post-index and at maximum follow-up in the following cohorts: GPP-only, Plaque-PsO-only, GPP + PsO, All-GPP, and general population. Propensity score matching was used to balance covariates between cohorts. The index date was the first medical claim for GPP (ICD-10 code L40.1) or PsO (L40.0), and a randomly selected date per year for individuals in the general population cohort.

Results

1246 patients were included in GPP-only, 1384 in GPP + PsO, 2630 in All-GPP and 127,540 in plaque-PsO-only. 19,641,441 individuals were included in general population. The maximum follow-up ranged from 36.14 to 41.28 months (3.01-3.44 years). At 365-day follow-up, mortality risk was significantly higher in the All-GPP vs the general population (hazard ratio [HR] 4.93, 95% confidence interval [CI] 2.24-10.88) and plaque-PsO-only (HR 2.31, 95% CI 1.32-4.04) cohorts. At maximum follow-up, the mortality risk for the All-GPP cohort was four times higher than the general population (HR 3.98, 95% CI 2.92-5.43) and 1.5 times higher than the plaque-PsO-only (HR 1.49, 95% CI 1.20-1.85) cohorts.

Conclusion

Patients with GPP exhibited an elevated mortality risk in comparison to the matched plaque-PsO and general population cohorts.

Keywords: generalized pustular psoriasis, plaque psoriasis, mortality risk, all-cause mortality, United States, medical claims, observational study

Introduction

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogeneous, and potentially life-threatening inflammatory skin disease.1-4 While GPP is distinct from plaque psoriasis (PsO), the two conditions often exhibit a strong correlation, with GPP tending to frequently associate with a prior plaque PsO condition (reported in 31%-78% of cases).1,2,4-6 GPP is characterized by disease flares and periods of partial or complete remission.1-4 Flares are associated with painful skin lesions and systemic symptoms, such as fever, which can negatively impact quality of life,1,3 and life-threatening complications and death can occur in some cases.1,2,4

The course of GPP is heterogeneous and highly unpredictable as flares can vary widely between patients in terms of frequency, duration, and severity.1-4 While some patients' symptoms may resolve with limited intervention, others may require more aggressive treatments. 1 Additionally, residual symptoms may persist despite therapeutic efforts. 4

An initial study conducted in 1971 reported a GPP mortality rate of 32%. 7 However, recent research reported lower mortality rates ranging from 2% to 7%, likely due to the availability of novel therapies such as GPP-specific biologics (approved in Japan).8,9 However, no GPP-specific biologics were approved in the United States (US) until recently.8,9 In 2022, spesolimab, an anti-interleukin-36 receptor monoclonal antibody, was the first GPP-specific treatment approved to treat GPP flares in adults. 10 Spesolimab recently received extended approval for treating GPP in patients aged 12 years and older, weighing ≥ 40 kg, in both the US and China.11,12 Although most studies on mortality in GPP do not report the cause of death, mortality due to flares is estimated to occur in approximately 5% to 10% of patients with GPP.13-15 The in-hospital mortality rate for patients with GPP is 4.2%, with higher rates observed in patients treated with systemic corticosteroid monotherapy compared with biologics (9.1% and 1.0%, respectively). 16

Mortality in GPP is often associated with complications such as sepsis, acute respiratory distress syndrome and heart failure.14,17 A recent review concluded that among studies reporting such data, sepsis/septic shock and cardiovascular complications were the most common cause of death in GPP. 8 Additional data are required to gain a comprehensive understanding of the disease burden and mortality associated with GPP. This information is crucial for advancing the development of innovative treatments capable of addressing both morbidity and mortality effectively.

The objective of this study was to compare all-cause mortality among patients with GPP to matched populations of patients with plaque PsO and the general population without GPP or plaque PsO.

Patients and methods

Study design

A non-interventional, observational, cohort study utilizing existing US claims data was conducted to investigate the all-cause mortality associated with GPP. The study used closed medical and prescription claims data from Inovalon® Insights LLC, which were derived and linked to an outside source of mortality data known as Datavant. Datavant is estimated to have captured approximately 85% of all deaths in the US between January 1, 2015 and December 31, 2020 (which includes the pre-index, selection and post-index periods). The data source selected for this study is representative of the insured US population and includes roughly 150 million covered lives from 2015 to 2020, including individuals insured with commercial, Medicaid-managed care, and Medicare Advantage plans. This diverse representation ensures that the study’s findings are applicable to a wide spectrum of real-world scenarios in the US. The utilization of these data adhered to the standards of the Health Insurance Portability and Accountability Act. The study received Institutional Review Board ethics review and approval.

Patient selection

The study included patients with GPP or plaque PsO who had ≥ 1 medical claim with an International Classification of Disease, 10th revision (ICD-10) diagnosis. Specifically, ≥ 1 inpatient medical claim with an ICD-10 diagnosis from January 1, 2016 to December 31, 2019 (selection period) or ≥ 2 outpatient claims ≥ 30 days apart from January 1, 2015 and December 31, 2020. Patients who were continuously enrolled in medical and prescription insurance 365 days post-index or until the date of death (if occurring during the 365 days post-index period) were included.

Patients were categorized into five cohorts: those with GPP only (GPP-only), those with GPP and plaque PsO (GPP + PsO), those with plaque PsO only (plaque PsO-only), a combined cohort of GPP-only and GPP + PsO (All-GPP), and a cohort representing the general population. Within the GPP-only, GPP + PsO, and plaque PsO-only cohorts, patients were identified and categorized during the selection period. Patients were identified using ICD-10 information from medical claims. The index date for the GPP-only, GPP + PsO and All-GPP cohorts was defined as the date for the first medical claim with an ICD-10 code (in any position) of L40.1 (GPP) during the selection period for patients that met all eligibility criteria. While, for the plaque PsO-only cohort, the index date was defined as the first medical claim with an ICD-10 code (in any position) of L40.0 (psoriasis vulgaris) during the selection period for eligible patients. The index date for the general population cohort was defined as a randomly selected date for each year during the selection period for patients that met all eligibility requirements (patients meeting the inclusion criteria without a medical claim for GPP or plaque PsO during the pre- and post-index periods). The inclusion and exclusion criteria are listed in Table S1.

Outcomes measured

All-cause mortality was assessed across two distinct timeframes: a 365-day post-index diagnosis period and a maximum follow-up duration for each patient, extending until either the conclusion of the study period or the patient experienced an event. Time-to-event data were assessed from “index-claim-2” to the maximum available follow-up time until December 31, 2020. The risk of all-cause mortality was assessed from the index date to the maximum available follow-up time until December 31, 2020. Other variables included were index year (spanning from 2016 to 2019), age, sex, insurance type, region, and the Charlson Comorbidity Index (CCI). The CCI was calculated according to a range of chronic conditions (including diabetes without chronic complication, diabetes with chronic complication, chronic pulmonary disease, rheumatic disease, congestive heart failure, mild liver disease, peripheral vascular disease, renal disease, any malignancy, cerebrovascular disease, myocardial infarction, dementia, hemiplegia or paraplegia, metastatic solid tumor, moderate or severe liver disease, peptic ulcer disease, and acquired immunodeficiency syndrome/human immunodeficiency virus [AIDS/HIV]) observed within the 365-day pre-index period. This index served as an important metric for assessing the burden of comorbidities and its influence on mortality.18-20

Statistical analyses

Baseline characteristics were summarized with frequencies for categorical variables and means with standard deviations (SD) for continuous variables across all cohorts. To establish balanced comparison groups, Greedy caliper propensity score matching was employed, pairing patients with GPP at a 1:2 ratio with those from the plaque PsO-only and general population cohorts. Matched variables included age, sex, insurance type, and index year.

Chi-square tests were utilized to assess the proportion of patients with any all-cause mortality across cohorts. The risk of all-cause mortality was evaluated using Cox proportional hazards models, adjusting for age, sex, region, insurance type, index year and CCI. Comparative assessments were made as follows: GPP-only vs plaque PsO-only, All-GPP vs plaque PsO-only, All-GPP vs general population, GPP + PsO vs plaque PsO-only, GPP + PsO vs general population, and plaque PsO-only vs general population. A significance level of <0.05 was predetermined as the criterion for statistical significance. All statistical analyses were performed using SAS 9.4 or R.

Results

Patient characteristics

Between January 1, 2015 and December 31, 2020, a total of 1246 patients were identified with GPP-only, while 1384 patients had both GPP and plaque PsO. The All-GPP cohort therefore included 2630 patients. A total of 127,540 patients were included in the plaque PsO-only cohort, and the general population cohort included 19,641,441 individuals (Table 1). Across all cohorts, most patients were female, with percentages ranging from 53.0% to 62.6%. Most patients had commercial insurance, varying from 54.8% to 73.2%. The GPP-only cohort revealed a significantly higher mean (SD) CCI score of 1.48 (2.18) compared with the plaque PsO-only and general population cohorts, with mean (SD) CCI scores of 0.94 (1.71) and 0.75 (1.59), respectively (P < 0.001). Similarly, a significantly higher mean (SD) CCI score was exhibited in the GPP + PsO cohort (1.53 [2.16]) compared with the plaque PsO-only and general population cohorts (0.94 [1.71] and 0.75 [1.59], respectively, P < 0.001). Furthermore, the age of the GPP-only and GPP + PsO cohorts was higher at the index date than the plaque PsO-only and general population cohorts, with respective mean (SD) ages of 53.9 (17.4), 52.9 (16.4), 50.8 (16.6) and 46.7 (17.2) years (P < 0.001) (Table 1). The maximum follow-up duration ranged from 36.14 months (3.01 years) to 41.28 months (3.44 years) across the cohorts.

Table 1.

Cohort Demographics.

Variable GPP-only (n = 1246) Comorbid GPP + PsO (n = 1384) Plaque PsO-only (n = 127,540) General population (n = 19,641,441) All-GPP (n = 2630)
Index year, n (%)
 2016 520 (41.7) 618 (44.7) 57,234 (44.9) 15,935,507 (81.1) 1138 (43.3)
 2017 259 (20.8) 333 (24.1) 30,043 (23.6) 1,288,978 (6.6) 592 (22.5)
 2018 260 (20.9) 233 (16.8) 22,926 (18.0) 656,736 (3.3) 493 (18.7)
 2019 207 (16.6) 200 (14.5) 17,337 (13.6) 1,760,220 (9.0) 407 (15.5)
Sex, n (%)
 Female 776 (62.3) 867 (62.6) 67,548 (53.0) 10,633,411 (54.1) 1643 (62.5)
 Male 470 (37.7) 517 (37.4) 59,992 (47.0) 9,008,030 (45.9) 987 (37.5)
Insurance type, n (%)
 Commercial 683 (54.8) 795 (57.4) 93,308 (73.2) 11,663,868 (59.4) 1478 (56.2)
 Medicaid 376 (30.2) 430 (31.1) 21,910 (17.2) 5,724,463 (29.1) 806 (30.6)
 Medicare advantage 187 (15.0) 159 (11.5) 12,322 (9.7) 2,253,110 (11.5) 346 (13.2)
Region, n (%)
 Midwest 334 (26.8) 337 (24.3) 36,928 (29.0) 4,734,851 (24.1) 671 (25.5)
 Northeast 256 (20.5) 279 (20.2) 27,179 (21.3) 3,324,571 (16.9) 535 (20.3)
 South 457 (36.7) 533 (38.5) 38,963 (30.5) 6,427,700 (32.7) 990 (37.6)
 West 199 (16.0) 235 (17.0) 24,470 (19.2) 5,154,319 (26.2) 434 (16.5)
Age at index
 Mean (SD) 53.9 (17.4) 52.9 (16.4) 50.8 (16.6) 46.7 (17.2) 53.3 (16.9)
Age group, n (%)
 18-24 28 (2.2) 38 (2.7) 6923 (5.4) 2,663,752 (13.6) 66 (2.5)
 25-34 99 (7.9) 115 (8.3) 13,114 (10.3) 2,869,280 (14.6) 214 (8.1)
 35-44 177 (14.2) 226 (16.3) 21,330 (16.7) 3,252,043 (16.6) 403 (15.3)
 45-54 288 (23.1) 326 (23.6) 30,512 (23.9) 3,850,775 (19.6) 614 (23.3)
 55-64 446 (35.8) 464 (33.5) 37,761 (29.6) 4,063,681 (20.7) 910 (34.6)
 65-74 139 (11.2) 166 (12.0) 12,641 (9.9) 1,847,695 (9.4) 305 (11.6)
 ≥75 69 (5.5) 49 (3.5) 5259 (4.1) 1,094,215 (5.6) 118 (4.5)
CCI (total)
 Mean (SD) 1.48 (2.18) 1.53 (2.16) 0.94 (1.71) 0.75 (1.59) 1.51 (2.17)

CCI, Charlson Comorbidity Index; GPP, generalized pustular psoriasis; PsO, psoriasis; SD, standard deviation.

All-cause mortality

At the 365-day follow-up (unadjusted), the All-GPP cohort demonstrated an almost 3-fold higher mortality rate compared with the plaque PsO-only cohort (1.1% vs 0.4%, P = 0.003) and a more than five times higher mortality rate than the general population cohort (1.1% vs 0.2%, P < 0.001) (Figure 1). Similarly, the GPP + PsO cohort had a mortality rate over three times higher than that of the plaque PsO-only cohort (1.1% vs 0.3%, P = 0.002) and over five times higher than the general population cohort (1.1% vs 0.2%, P < 0.001). The mortality rate in the GPP-only and plaque PsO-only cohorts was 1.0% and 0.5%, respectively (P = 0.195) (Figure 1).

Figure 1.

Figure 1.

Mortality rate by propensity-matched cohorts at 365 days post-index (unadjusted). All comparisons significant at P < 0.05 level except for GPP-only vs PsO-only. GPP, generalized pustular psoriasis; PsO, psoriasis.

At the maximum follow-up (unadjusted), differences in mortality rates persisted across the cohorts. The GPP-only cohort displayed an almost 1.5 times higher mortality rate compared with the plaque PsO-only cohort (5.7% vs 3.9%, P = 0.036) (Figure 2). Compared with the plaque PsO-only and general population cohorts, the All-GPP cohort had significantly higher mortality rates (5.7% vs 3.6%, P < 0.001; 5.7% vs 1.2%, P < 0.001, respectively). Similarly in comparison to the plaque PsO-only and general population cohorts, the GPP + PsO cohort showed significantly higher mortality rates (5.6% vs 3.4%, P = 0.001; 5.6% vs 1.2%, P < 0.001, respectively) (Figure 2).

Figure 2.

Figure 2.

Mortality rate by propensity-matched cohorts at maximum follow-up (unadjusted). All comparisons significant at P < 0.05 level. GPP, generalized pustular psoriasis; PsO, psoriasis.

Mortality risk

At 365 days of follow-up (adjusted), the All-GPP cohort showed a significantly higher risk of mortality compared with both the plaque PsO-only and general population cohorts (HR 2.57, 95% CI 1.47-4.49, P < 0.001; HR 6.30, 95% CI 2.97-13.34, P < 0.001, respectively) (Figure 3). Furthermore, the GPP + PsO cohort demonstrated a significantly elevated risk of mortality when compared with both the plaque PsO-only and general population cohorts (HR 3.37, 95% CI 1.47-7.69, P = 0.004; HR 5.04, 95% CI 1.96-13.00, P = 0.001, respectively) (Figure 3). The plaque PsO-only cohort had a significantly higher risk of mortality than the general population (HR 3.32, 95% CI 2.84-3.89, P < 0.001). The HR for mortality risk in the GPP-only vs plaque PsO-only cohorts was 2.04 (95% CI 0.94-4.39), although this comparison did not reach statistical significance (P = 0.070).

Figure 3.

Figure 3.

Mortality risk by propensity-matched cohorts at 365 days post-index (adjusted). All comparisons significant at P < 0.05 level except for GPP-only vs PsO-only. GPP, generalized pustular psoriasis; LCI, lower confidence interval; PsO, psoriasis; UCI, upper confidence interval.

At the maximum follow-up (adjusted), the GPP-only and All-GPP cohorts exhibited over 1.5 times higher risk of mortality than the plaque PsO-only cohort (HR 1.55, 95% CI 1.14-2.11, P = 0.005; HR 1.61, 95% CI 1.30-1.99, P < 0.001, respectively) (Figure 4). In addition, the All-GPP cohort demonstrated a mortality risk of nearly five times higher than that of the general population cohort (HR 4.80, 95% CI 3.59-6.42, P < 0.001). In the GPP + PsO cohort, the risk of mortality surpassed 1.5 times that of the plaque PsO-only cohort (HR 1.59, 95% CI 1.19-2.14, P = 0.002) (Figure 4). Additionally, when compared with the general population, the GPP + PsO cohort exhibited an almost 5-fold higher risk of mortality (HR 4.76, 95% CI 3.19-7.12, P < 0.001). The plaque PsO-only cohort had a significantly higher risk of mortality than general population (HR 3.10, 95% CI 2.94-3.27, P < 0.001).

Figure 4.

Figure 4.

Mortality risk by propensity-matched cohorts at maximum follow-up (adjusted). All comparisons significant at P < 0.05 level. GPP, generalized pustular psoriasis; LCI, lower confidence interval; PsO, psoriasis; UCI, upper confidence interval.

After adjusting for CCI at 365 days of follow-up, the All-GPP cohort showed significantly higher mortality risk compared with both the plaque PsO-only and general population cohorts (HR 2.31, 95% CI 1.32-4.04, P = 0.004 vs HR 4.93, 95% CI 2.24-10.88, P < 0.001) (Figure S1). The GPP + PsO cohort also demonstrated higher risk compared with the plaque PsO-only cohort (HR 2.67, 95% CI 1.15-6.20, P = 0.022). Similarly, both the GPP + PsO and plaque PsO-only cohorts had a significantly higher mortality risk than the general population cohort (HR 4.08, 95% CI 1.47-11.38, P = 0.007; HR 3.65, 95% CI 3.06-4.35, P < 0.001, respectively). The GPP-only and plaque PsO-only comparison was not statistically significant (HR 1.90, 95% CI 0.88-4.14, P = 0.104) (Figure S1).

After adjusting for CCI at the maximum follow-up, the GPP-only cohort had nearly 1.5 times higher mortality risk than the plaque PsO-only cohort (HR 1.49, 95% CI 1.10-2.03, P = 0.011) (Figure S1). Similarly, the All-GPP cohort exhibited a 1.5-fold higher risk to the plaque PsO-only cohort (HR 1.49, 95% CI 1.20-1.85, P < 0.01), and nearly 4-fold higher risk compared with the general population cohort (HR 3.98, 95% CI 2.92-5.43, P < 0.001). Additionally, compared with the plaque PsO-only cohort, the GPP + PsO cohort had a 1.4 times higher risk of mortality (HR 1.41, 95% CI 1.05-1.09, P = 0.023). Both GPP + PsO and plaque PsO-only cohorts demonstrated significantly higher risks, with 3.4 (HR 3.44, 95% CI 2.26-5.22, P < 0.001) and 2.9 (HR 2.90, 95% CI 2.74-3.08, P < 0.001) times higher mortality rates, respectively, compared with the general population (Figure S1).

Kaplan-Meier curves showed that at both 365 days post-index (Figure S2) and at maximum follow-up (Figure S3), the All-GPP cohort had significantly lower survival probabilities compared with the general population. Similar trends were observed when comparing the survival probabilities of the All-GPP cohort with the plaque PsO-only cohort at both timepoints (Figure S4; Figure S5, respectively). While survival probability was not significantly different between the GPP-only and plaque PsO-only cohorts at 365 days post-index (Figure S6), this became significant when considering the maximum follow-up period (Figure S7).

Discussion

This study showed that patients with GPP had higher mortality rates than patients with plaque PsO, though this comparison was only statistically significant at the maximum follow-up period. Specifically, the mortality rate in the GPP-only cohort was 1.0% at the 365-day follow-up and 5.7% at the maximum follow-up, which is consistent with more recent studies reporting GPP mortality rates between 2% and 16%.5,21

Increased awareness of mortality risks in GPP may lead to better identification of the causes of mortality, development of optimized treatment, and better outcomes for patients. In a literature review, studies conducted in the last two decades reported lower mortality rates (0.2 deaths per 100 patient-years) compared with older studies before 2000 (1.6 deaths per 100 patient-years). 8 However, a 2022 study reported an overall mortality rate of 4.3% in hospitalized patients with GPP. 16 While mortality rates have declined due to the use of new off-label treatments, rates remain high in comparison with other forms of psoriasis, although erythrodermic psoriasis, which has overlapping clinical features with GPP, is also potentially fatal.8,22 This underscores the need for improved treatment options, expanded use of the available options, and more effective clinical management of acute, generalized forms of psoriasis and psoriasis flares.

The GPP in-hospital mortality rate was significantly lower in patients receiving biologics (1.0%) compared with those receiving oral agents (3.7%) or corticosteroids (9.1%).8,16,23 These findings may suggest that biologics contribute to improved outcomes for patients with GPP. However, there are limited studies on drug survival within the context of GPP disease severity that might help evaluate the efficacy of biologics throughout the disease course. The studies that do exist demonstrate random treatment selection and poor long-term adherence. These variable treatment patterns also highlight the unmet need for effective and well tolerated GPP therapies, essential for long-term treatment management and patient adherence.16,24-26 Interestingly, the use of biologics leads to lower rates of comorbidities as well as lower mortality rates.5,16 Future research could explore the extent to which maintenance therapy with biologics suppresses chronic inflammation and reduces comorbidities thereby reducing mortality, in addition to having a direct effect on prevention or treatment of life-threatening flares.

A limitation of this study is the absence of specific causes of mortality in the database, making it challenging to ascertain if mortality was attributed to GPP flares, GPP-related comorbidities, or other factors. The substantially higher HR during the 365-day follow-up compared with the respective numbers of the maximum follow-up period indicates that the mortality might be related directly to the incidence of flares or in the follow-up time of flares. However, it is worth noting that a recent review found that most studies reporting GPP mortality rates do not provide cause of death, which is not surprising as a causal relationship might not be obvious for many cases. 8 Of studies that did, some found the cause of death to be directly related to GPP,15,24,27 with common causes including sepsis/septic shock and cardiovascular complications. 8 Further research is necessary to characterize the causes of mortality among patients with GPP and the impact of treatment in preventing patient morbidity and mortality.

In conclusion, patients with GPP demonstrated a higher risk of all-cause mortality in GPP compared with both matched plaque PsO and general population cohorts. The risk of mortality was more than four times higher in patients with GPP compared with the general population and more than 1.5 times higher than that of patients with plaque PsO. These findings fill a significant gap in the existing literature and highlight both the need for increased awareness of the mortality burden in GPP and the need for continuous treatment options for patients with GPP both during and after flares.

Supplemental Material

Supplemental Material - All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis

Supplemental Material for All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis by Alice B. Gottlieb, Hannah Crooke Kwiatkowski, Juan Semeco, Bhargav Lakshminarasimhan, Bruce Strober, and Mark Lebwohl in Journal of Psoriasis and Psoriatic Arthritis®

Acknowledgements

The authors would like to acknowledge the contributions of Layla Lavasani of Boehringer Ingelheim for discussions supporting development of the manuscript. The authors also thank Bridget Balkaran from Cerner Enviza (now Oracle) for support with statistical analysis for the study. Julia Poritz, PhD, and Shilpa Chennakrishnaiah, PhD, of Cytel Inc, Waltham, MA, US, provided writing and editorial support which was contracted and funded by Boehringer Ingelheim. Samantha Lommano, PhD, and Michael Riley, PhD, of Bioscript Group, Macclesfield, UK, provided editorial support with the final draft (including submission to the journal), funded by Boehringer Ingelheim.

Author contributions: All authors contributed to the conceptualization/interpretation and writing of the manuscript.

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ABG has received research/educational grants from Avalo Therapeutics, Bristol Myers Squibb, Janssen, Moonlake, and UCB Pharma (all paid to Mount Sinai School of Medicine); and honoraria as an advisory board member and consultant for Amgen, Eli Lilly, Highlights Therapeutics, Janssen, Novartis, Sanofi, Sun Pharma, Takeda, Teva, UCB, and XBiotech (stock options for RA). BS reports honoraria as a consultant or speaker for AbbVie, Acelyrin, Alamar, Almirall, Alumis, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Eli Lilly, Imagenebio, Incyte, Janssen, Kangpu Pharmaceuticals, Leo, Maruho, Meiji Seika Pharma, Monte Carlo, Novartis, Okura, Pfizer, Protagonist, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, Takeda, UCB Pharma, Union Therapeutics; stock options from Connect Biopharma and Mindera Health; consulting fees from CorEvitas Psoriasis Registry (Scientific Co-Director and Investigator); and honorarium from the Journal of Psoriasis and Psoriatic Arthritis (Editor-in-Chief). ML is an employee of Mount Sinai; receives research funds from Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. HK, JS, and BL are employees of Boehringer Ingelheim.

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Boehringer Ingelheim. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. The authors did not receive payment related to the development of the manuscript.

Supplemental Material: Supplemental material for this article is available online.

Ethical Statement

Ethical Approval

The study received Institutional Review Board ethics review and approval. The use of data adhered to the standards of the Health Insurance Portability and Accountability Act.

Informed Consent

Informed consent to participate was not required as the study was conducted retrospectively using available claims data.

ORCID iDs

Bruce Strober https://orcid.org/0000-0002-8394-2057

Mark Lebwohl https://orcid.org/0000-0002-4705-5303

Data Availability Statement

The data underlying this article are available in the article.*

References

  • 1.Crowley JJ, Pariser DM, Yamauchi PS. A brief guide to pustular psoriasis for primary care providers. Postgrad Med J. 2021;133(3):330-344. doi: 10.1080/00325481.2020.1831315 [DOI] [PubMed] [Google Scholar]
  • 2.Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919. doi: 10.1080/1744666x.2019.1648209 [DOI] [PubMed] [Google Scholar]
  • 3.Hanna ML, Singer D, Bender SD, Valdecantos WC, Wu JJ. Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. Curr Med Res Opin. 2021;37(10):1697-1703. doi: 10.1080/03007995.2021.1951192 [DOI] [PubMed] [Google Scholar]
  • 4.Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona Registry dermatologists. Dermatol Ther. 2021;11(2):529-541. doi: 10.1007/s13555-021-00493-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):21-29. doi: 10.1007/s40257-021-00654-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rivera-Diaz R, Dauden E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther. 2023;13(3):673-688. doi: 10.1007/s13555-022-00881-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br J Dermatol. 1971;85(5):407-411. doi: 10.1111/j.1365-2133.1971.tb14044.x [DOI] [PubMed] [Google Scholar]
  • 8.Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256-273. doi: 10.1111/jdv.18720 [DOI] [PubMed] [Google Scholar]
  • 9.Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. doi: 10.1080/1744666x.2019.1708193 [DOI] [PubMed] [Google Scholar]
  • 10.FDA . FDA approves spesolimab-sbzo, the first treatment option for generalized pustular psoriasis flares in adults. https://www.fda.gov/drugs/novel-drug-approvals-fda/new-drug-therapy-approvals-2022. Accessed 8 April, 2024.
  • 11.FDA . SPEVIGO (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761244s003lbl.pdf. Accessed 29 April, 2024. [PubMed]
  • 12.National Medical Products Administration . Drug Approval Document Release. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20240311135849130.html (nmpa.gov.cn). Accessed 29 April, 2024.
  • 13.Jin H, Cho HH, Kim WJ, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42(7):674-678. doi: 10.1111/1346-8138.12863 [DOI] [PubMed] [Google Scholar]
  • 14.Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676-684. doi: 10.1111/ijd.12070 [DOI] [PubMed] [Google Scholar]
  • 15.Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669-673. doi: 10.1684/ejd.2006.0003 [DOI] [PubMed] [Google Scholar]
  • 16.Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266-1274. doi: 10.1016/j.jaad.2021.06.008 [DOI] [PubMed] [Google Scholar]
  • 17.Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651. doi: 10.1111/jdv.14949 [DOI] [PubMed] [Google Scholar]
  • 18.Huang Y-Q, Gou R, Diao Y-S, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ - Sci B. 2014;15(1):58-66. doi: 10.1631/jzus.B1300109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8-35. doi: 10.1159/000521288 [DOI] [PubMed] [Google Scholar]
  • 20.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi: 10.1016/0021-9681(87)90171-8 [DOI] [PubMed] [Google Scholar]
  • 21.Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033-1047. doi: 10.1080/1744666x.2022.2116003 [DOI] [PubMed] [Google Scholar]
  • 22.Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79-82. doi: 10.14744/nci.2016.16023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hsu C-K, Huang Y-H, Chang C-H, et al. Taiwanese Dermatological Association consensus recommendations for the diagnosis, treatment, and management of generalized pustular psoriasis. Dermatol Sin. 2024;42(2):98-109. doi: 10.4103/ds.DS-D-24-00070 [DOI] [Google Scholar]
  • 24.Kromer C, Loewe E, Schaarschmidt ML, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34(2):e14814. doi: 10.1111/dth.14814 [DOI] [PubMed] [Google Scholar]
  • 25.Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33-40. doi: 10.1111/1346-8138.15146 [DOI] [PubMed] [Google Scholar]
  • 26.Tada Y, Guan J, Iwasaki R, Morita A. Treatment patterns and drug survival for generalized pustular psoriasis: a patient journey study using a Japanese claims database. J Dermatol. 2024;51(3):391-402. doi: 10.1111/1346-8138.17097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Borges-Costa J, Silva R, Gonçalves L, Filipe P, Soares de Almeida L, Marques Gomes M. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271-276. doi: 10.2165/11586900-000000000-00000 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material - All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis

Supplemental Material for All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis by Alice B. Gottlieb, Hannah Crooke Kwiatkowski, Juan Semeco, Bhargav Lakshminarasimhan, Bruce Strober, and Mark Lebwohl in Journal of Psoriasis and Psoriatic Arthritis®

Data Availability Statement

The data underlying this article are available in the article.*


Articles from Journal of Psoriasis and Psoriatic Arthritis are provided here courtesy of SAGE Publications

RESOURCES